HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because just a small amount of CBD it is quite expensive.Thus making CBD business incredibly lucrative to investors, and shareholders alike.
A little known CBD company CIIX (Chineseinvestors.com, Inc.) out of Los Angeles, CA. has caught our full and undivided attention.CIIX closed trading Friday at $0.645, while SeeThru Equity has released research report on the company with a price target of $3.75.Start doing your own research on CIIX immediately before the crowd discovers it.CIIX is starting to receive increased attention from the investing public, but it is still early.CIIX has an exciting CBD business, through its wholly owned subsidiary ChineseHempOil, Inc. and its websites ChineseCBDOil.com and ChineseHempOil.com for online retail, and direct sales of hemp based CBD products.CIIX is planning a major revenue expansion domestically and globally for its CBD/Hemp based business.Make sure CIIX is at the top of your watchlist.
During the 2016 campaign President Trump commented about medical marijuana: "I'm in favor of it 100%." Former Speaker of the House John Boehner, who once stated he was "unalterably opposed" to legalization, now admits: "My thinking on cannabis has evolved." Today, he sits on the advisory board of a major marijuana company. The United States Attorney General Jeff Sessions, once completely against legislation favoring marijuana, now says: "There may well be some benefits from medical marijuana."
These companies are set to explode: Chineseinvestors.com, Inc. (CIIX), GW Pharmaceuticals Plc. (GWPH), Aurora Cannabis (ACBFF), Cara Therapeutics Inc. (CARA), Zynerba Pharmaceuticals Inc. (ZYNE).
Chineseinvestors.com, Inc. (CIIX)
Market Cap: $16.65M, current share price: $0.52
ChineseInvestors.com, Inc. is responsible for the online and retail sales of hemp-based health products in the United States and has been building awareness for its 'Opt Hemp' brand among Chinese consumers in the U.S. since its establishment in April 2017. In June 2017, the Company officially opened its first retail location known as Chinese Wellness Center and launched its website www.chinesehempoil.com. They also currently work with Medicine Man Denver on the creation of a new intellectual property and will be providing licensing and consulting services within the emerging Cannabis sector.
GW Pharmaceuticals plc, is a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of efractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.
Micron Waste Technologies Inc. reported positive results from the optimization of the Cannavore™ cannabis waste processing units with Aurora Cannabis Inc.. The Company will now optimize the technology for sub-zero operations, as well as add computerized remote operating capabilities, following which Micron will commence to offer the units commercially.
Cara Therapeutics Inc. (NASDAQ:CARA)
Market Cap: $832.96M, current share price: $21.20
Cara Therapeutics, Inc. is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute postoperative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan.
Zynerba Pharmaceuticals, Inc. focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.ACR Communication, LLC has been compensated one thousand dollars cash for this article and tweleve thousand dollars total by Regal Consulting. LLC, for news commentary articles for CIIX.CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article.This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.We may buy or sell additional shares of CIIX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
